French deal sees peptide maker acquired by Provence Technologies

By Fiona Barry

- Last updated on GMT

French deal sees peptide maker acquired by Provence Technologies

Related tags Peptide synthesis Active ingredient

Provence Technologies, a French chemical developer, has acquired the active pharmaceutical ingredient (API) maker Synprosis, a specialist in synthesising long-chain peptides.

Michel Feraud, Provence CEO, told in-Pharmatechnologist.com his group acquired Synprosis for this patented long-chain technology.

For long chains the only way right now is to produce them using biologic agents. But with Synprosis’s patent we will be able to offer an alternative route produced by chemical [agents] to increase their purity and safety.

This is a way to produce longer and purer peptides with low-cost production.”

Synprosis’s method, called “SEA Ligation” is a native chemical ligation which joins a bis(2-sulfanylethyl)amino (SEA) peptide with a cysteinyl or homocysteinyl peptide, giving access to proteins.

Synprosis’s technology for increased peptide production lowers costs by 30 to 40 per cent, Provence said.

Peptide plans

Developing the newly acquired purer chains will allow Provence to supply peptides to big pharma in a CMO (contract manufacturing organisation) capacity, Feraud told us. The Synprosis subsidiary will also produce good-quality peptides for use within the Provence Group.

Synprosis will be integrated into Provepep, the Provence group’s peptide-producing division. Jean-Pierre Salles, who founded Synprosis, will retain an executive role within Provepep. Provence is also owns Propharm, a pharmaceutical ingredients wing.

For its existing APIs, Provence performs R&D and outsources the production of large volumes to CMOs (contract manufacturing organisations) including Novasep.

Synprosis is based in Aix-en-Provence, France, while Provence is headquartered in the nearby city of Marseille. Financial terms of the agreement were not disclosed.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...